Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis

Pfizer reported flat Q3 revenue of $16.6B, raising full-year guidance to $62B-$64B. Eliquis sales grew 25% to $2.52B, offsetting declines in COVID-related products. Adjusted EPS held at $0.87. Shares slipped 0.2% premarket. The company expects Medicare price impacts to be minimal.

Pfizer (PFE) reported Q3 earnings of $0.87 per share, beating estimates of $0.73, with revenue at $16.6B, also topping forecasts. Net income fell 8% to $3.24B. The company raised its 2023 adjusted earnings guidance to $2.95-$3.05 per share and revenue forecast to $62B-$64B, citing strong performance.

Pfizer raised its 2026 forecasts after strong Q3 results, driven by cancer drugs and Eliquis. Revenue was $16.58B, beating estimates. The company targets $62B-$64B in annual sales, up from prior forecasts. Adjusted EPS is expected to be $2.95-$3.05. Pfizer aims for $9.7B in cost savings by 2029. CEO Albert Bourla cited strong performance and confidence in growth prospects.

Pfizer reported Q3 earnings of $3.242B ($0.56/share), down from $3.541B ($0.62/share) last year. Adjusted earnings were $4.985B ($0.87/share). Revenue fell 0.4% to $16.583B. The company appointed Cecile Guegan as CFO. Shares rose 0.29% premarket.

Pfizer reported Q3 2026 revenue of $16.58B, down slightly YoY but up 7% excluding Comirnaty and Paxlovid. Full-year revenue guidance raised to $62B-$64B, with adjusted EPS of $2.95-$3.05. The outlook includes a $650M charge from an agreement with Innovent Biologics. Analysts expected lower revenue and EPS.

Pfizer (PFE) reported Q3 revenue of $16.6B, exceeding expectations of $15.9B, with adjusted EPS of 87 cents vs. estimates of 73 cents. The company raised its full-year guidance to $2.95-$3.05 EPS. Pfizer's stock is up 20% this year but remains down over 30% in five years, trading at a forward P/E of 10 and offering a 5.6% dividend yield.